Cancer

Cover image for Vol. 121 Issue 1

Edited By: Fadlo R. Khuri, MD

Impact Factor: 4.901

ISI Journal Citation Reports © Ranking: 2013: 38/203 (Oncology)

Online ISSN: 1097-0142

Associated Title(s): Cancer Cytopathology, CA: A Cancer Journal for Clinicians

Editorial Board


Editor-in-Chief

Fadlo R. Khuri, MD*, Emory University School of Medicine, Atlanta, Georgia
( canceredoff@cancer.org )


Section Editors 

Robert Bast, MD
Translational Research
UT MD Anderson Cancer Center
Houston, Texas  

Smita Bhatia, MD, MPH*
Outcomes Research  
City of Hope Comprehensive Cancer Center
Duarte, California

Steven A. Curley, MD
Gastrointestinal Disease
Baylor College of Medicine
Houston, Texas 

Jeremy J. Erasmus, MBBCh*
Diagnostic Imaging
UT MD Anderson Cancer Center
Houston, Texas

Robert L. Ferris, MD, PhD
Endocrine Disease
Head and Neck Disease
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania

Henry Friedman, MD
Neuro-oncology
Duke Medical Center
Durham, North Carolina

Donna Greenberg, MD*
Psychosocial Oncology
Massachusetts General Hospital
Boston, Massachusetts

Michael T. Halpern, MD, PhD*
Disparities Research 
University of Arizona
Tucson, Arizona

H. Jean Khoury, MD*
Hematologic Malignancies
Emory University School of Medicine
Atlanta, Georgia

Elise Kohn, MD*
Gynecologic Oncology
National Institutes of Health
Bethesda, Maryland

Badrinath Konety, MD
Genitourinary Disease
University of Minnesota
Minneapolis, Minnesota

Kim A. Margolin, MD*
Melanoma and Skin
Stanford University
Stanford, California

Susan O'Brien, MD
Hematologic Malignancies
UT MD Anderson Cancer Center
Houston, Texas

Ruth O'Regan, MD
Breast Disease
Emory University School of Medicine
Atlanta, Georgia

Electra D. Paskett, PhD, MPH
Epidemiology
The Ohio State University
Columbus, Ohio

Suresh S. Ramalingam, MD
Chest and Lung Disease
Clinical Trials
Medical Oncology
Emory University School of Medicine
Atlanta, Georgia

Chandrajit Raut, MD
Soft Tissue and Bone Sarcoma
Brigham and Women's Hospital
Boston, Massachusetts

Walter M. Stadler, MD
Genitourinary Disease
The University of Chicago Medical Center
Chicago, Illinois

Kenneth K. Tanabe, MD
Hepatobiliary Tract
Massachusetts General Hospital
Boston, Massachusetts

Lynne I. Wagner, PhD
Symptom Control and Palliative Care
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Christopher G. Willett, MD*
Radiation Oncology
Duke University Medical Center
Durham, North Carolina

Patrick A. Zweidler-McKay, MD, PhD*
Pediatric Oncology
UT MD Anderson Cancer Center
Houston, Texas

Statistical Reviewers 

Lyle D. Broemeling, PhD

Suzanne Dahlberg, PhD

Elizabeth Garrett-Mayer, PhD

Yu Shyr, PhD

Editorial Staff

Esmeralda Galán Buchanan, Journals Director
Carissa A. Gilman, Managing Editor
Danyella Davis, Editorial Assistant
Antonio Shaw, Editorial Assistant


Dr. Bast receives royalties from Fujirebio Diagnostics for CA 125 and serves as an External Advisory Board member for Vermillion Diagnostics. He has no other financial relationships or interests to disclose.

Dr. Curley serves on the Scientific Advisory Board for Polaris Pharmaceuticals. He has no other financial relationships or interests to disclose.

Dr. Ferris has a consultant/advisory agreement with Bristol Myers-Squibb and with AstraZeneca/MedImmune. He receives research funding from VentiRx and Bristol Myers-Squibb. He has no other financial relationships or interests to disclose.

Dr. Friedman serves on medical advisory boards for American Brain Tumor Association, National Children’s Cancer Society, Pinnacle Care, and Voices Against Brain Cancer; the national advisory panel for EPSNW; as a special advisor for the Tug McGraw Foundation; on the medical and scientific board of advisors for the Rory David Deutsch Foundation; on the board of advisors for Earth Energies; and on the board of directors for Team Doctors Preferred Access. He also owns stock in Arno Therapeutics, receives honoraria and travel reimbursement as a consultant for Genentech, and has provided expert testimony for medical malpractice cases. He has no other financial relationships or interests to disclose.

Dr. Konety serves as a consultant for Photocure, GTx, and Axogen. He has also received travel reimbursement from Dendreon for a clinical trial. He has no other financial relationships or interests to disclose.

Dr. O’Brien serves as an advisor for The Leukemia and Lymphoma Society (no honorarium), an ex-officio scientific board member for Lymphoma Research Foundation (no honorarium), a scientific board member for CLL Global Research Foundation (no honorarium), and a consultant for Celgene. She has no other financial relationships or interests to disclose.

Dr. O’Regan has consultant/advisory agreements with Genomic Health, Novartis, and Genentech and has received travel reimbursement from Novartis and Roche. She has no other financial relationships or interests to disclose.

Dr. Paskett owns stock in Meridian Bioscience and Pfizer and receives research funding from Merck. She has no other financial relationships or interests to disclose.

Dr. Ramalingam has attended advisory board meetings for Amgen, ARIAD, Astra Zeneca, Aveo, Biodesix, Biothera, Boehringer Ingelheim, Celgene, Eli Lilly, Genentech, Gilead, and Novartis over the last 3 years. He has no other financial relationships or interests to disclose.

Dr. Raut is an author on 5 sections for UpToDate (all sarcoma-related). He has no other financial relationships or interests to disclose.

Dr. Stadler serves as an ad hoc editor for UpToDate, a scientific advisory board member for Kidney Cancer Association and Bladder Cancer Action Network, and a consultant for Bayer, Caremark/CVS, Genentech, Johnson & Johnson, MedPacto, Merck, Millennium, Veridex, Dendreon, NCI/SAIC-Frederick, and Sotio Pharmaceuticals. He also serves on the speakers bureaus for Imedex, CME Innovations, CME Incite, Research-to-Practice, Clinical Care Options, and Medical Communications Media. He has no other financial relationships or interests to disclose.

Dr. Tanabe serves as an associate editor for UpToDate (section editor, GI oncology) and a consultant for Best Doctors and LEK Consulting. He also serves on the Astellas scientific advisory board for enzalutamide for hepatocellular carcinoma and is an unpaid board member for Helix 12. He has no other financial relationships or interests to disclose.

Dr. Wagner serves as a consultant for Gilead. She has no other financial relationships or interests to disclose.

*No financial relationships or interests to disclose.

EDITORIAL BOARD

Jaffer A. Ajani, MD
Saro Armenian, DO, MPH
Andrea M. Barsevick, DNSc
Tracy Batchelor, MD, MPH
Marianne Berwick, PhD
Abenaa Brewster, MD, MHS
Harry B. Burke, MD, PhD
Betty Caan, DrPH
D. Ross Camidge, MD, PhD
Paul B. Chapman, MD
Amy Y. Chen, MD, MPH
Matthew Cooperberg, MD, MPH
Allan I. Covens, MD
Christopher H. Crane, MD
Anthony V. D’Amico, MD, PhD
Shaheenah Dawood, MBBCh, MRCP
Linda Duska, MD
Bassell El-Rayes, MD

David M. Euhus, MD
Michael J. Fisch, MD, MPH
Keith T. Flaherty, MD
Mona Fouad, MD, MPH
Shirish Gadgeel, MD
Ian Ganly, MD, PhD
Sharon H. Giordano, MD, MPH
Sally L. Glaser, PhD
Mary K. Gospodarowicz, MD
Dawn L. Hershman, MD
Jean Hurteau, MD
Robert T. Jensen, MD
Hagop M. Kantarjian, MD
Lisa B. Kenney, MD, MPH
Jonathan A. Ledermann, MD
Seth Lerner, MD
J. Rebecca Liu, MD
Robert G. Maki, MD, PhD

Viraj Master, MD, PhD
William M. Mendenhall, MD
William H. Meyer, MD
Matthew Milowsky, MD
Michael Morris, MD
Monica Morrow, MD
Taofeek K. Owonikoko, MD, PhD
Blase N. Polite, MD, MPP
Charles A. Powell, MD
David A. Reardon, MD
Aaron D. Schimmer, MD, PhD
Sonali M. Smith, MD
Anil K. Sood, MD
Erich Sturgis, MD, MPH
Ayalew Tefferi, MD
Mary Beth Terry, PhD
Amelia Zelnak, MD, MSc
Xin Zhang, MD, PhD


 

SEARCH

SEARCH BY CITATION